Expanding the nanotherapeutic toolbox for non-small-cell lung cancer
Authors:
- 1 January 2021
- journal article
- editorial
- Published by Elsevier in Annals of Oncology
- Vol. 32 (1) , 9-11
Abstract
No abstract availableFunding Information
- National Institutes of Health
This publication has 13 references indexed in Scilit:
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCNew England Journal of Medicine, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Cancer nanomedicine: progress, challenges and opportunitiesNature Reviews Cancer, 2016
- Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancerBiomaterials, 2014
- A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancerCancer Chemotherapy and Pharmacology, 2014
- Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III TrialJournal of Clinical Oncology, 2012
- Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological ProfileScience Translational Medicine, 2012
- Polymeric micelles for nano-scale drug deliveryReactive and Functional Polymers, 2011
- Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancerAnnals of Oncology, 2007
- Paclitaxel (Taxol)New England Journal of Medicine, 1995